Novaremed

About

Funding history · 6 rounds · $67.2M total

Headcount over time

Q&A

What is Novaremed's primary focus?

Novaremed is a clinical-stage biopharmaceutical company focused on developing non-opioid treatments for chronic pain and peripheral neuropathy.

What is Novaremed's lead product?

Novaremed's lead product is nispomeben (NRD.E1), an orally active non-opioid small molecule with FDA Fast Track Designation, currently in a Phase 2b clinical trial for painful diabetic peripheral neuropathy (PDPN).

When did Novaremed receive FDA Fast Track Designation for NRD.E1?

Novaremed received Fast Track Designation from the FDA for NRD.E1 for the treatment of painful diabetic peripheral neuropathy in December 2020.

What was Novaremed's most recent funding round?

In January 2021, Novaremed secured a B Round of $50,000,000 from investors including Global Emerging Markets (GEM).

What is the status of Novaremed's earlier-stage pipeline candidates?

Novaremed's earlier-stage pipeline includes MP-101 (Phase 2) for the prevention of chemotherapy-induced peripheral neuropathy (CIPN) and MP-103 (preclinical) also targeting CIPN and other peripheral neuropathy indications.

What is the employee count for Novaremed?

Novaremed has an employee count in the 1-10 range.

When was Novaremed founded?

Novaremed was founded in Israel in 2008.

Did Novaremed expand its pipeline through an acquisition recently?

Yes, in September 2021, Novaremed expanded its pipeline of non-opioid treatment candidates for chronic pain indications through the acquisition of Metys Pharmaceuticals.

Has Novaremed published clinical study data for NRD.E1?

Yes, in June 2022, Novaremed announced the publication of Phase 1 and Phase 2a study data for NRD.E1, demonstrating its potential as an investigational non-opioid pain treatment.

Team · 3

Eli Kaplan

Founder · Founder

Joseph Feinstein

Founder · Co-founder

Zvi Slonimsky

Founder · Co-Founder

Sectors & technology

Highlights

Tags